



QoN 01

Are you aware of Australia's obligations under Article 5.3 of World Health Organisation's Framework Convention on Tobacco Control "*in setting and implementing their public health policies with respect to tobacco control, Parties shall act to protect these policies from commercial and other vested interests of the tobacco industry in accordance with national law*"?

Yes we at CAPHRA are aware of Australia's obligations under Article 5.3.

QoN 02

Have you or your organisation received any support, whether financial or non-financial, direct or indirect, from any parties involved in the production, distribution or sale of tobacco, nicotine or vaping products?

Neither CAPHRA, or myself personally have received, at any time, any financial support from any parties involved in the production, distribution or sale of tobacco, nicotine or vaping products.

I did, however, consult with Eliana Golberstein from Myriad Pharmaceuticals in Auckland NZ, who are involved in the manufacture of nicotine and nicotine salts used for e-liquids in New Zealand, for editorial support of our submission, to double check the veracity of the chemistry references in the CAPHRA submission.

QoN 03

Have you or your organisation, received any support, whether financial or non-financial, direct or indirect, from associated entities of tobacco companies?

Neither CAPHRA, nor myself have received any financial or non financial, direct or indirect, support from associated entities of tobacco companies.



QoN 04

Have you received any assistance, or liaised or consulted with, any other person or organisation in the preparation of your evidence to this inquiry?

If yes, please provide the details of any persons and/or organisation that assisted, or with whom you liaised or consulted, in the preparation of your evidence to this inquiry, including:

- a. the name of the persons or organisation;
- b. the ABN or CAN, if applicable; and
- c. any other related information.

The submission from CAPHRA was an original document that was created with the editorial assistance of Myriad Pharmaceuticals of Auckland NZ. Eliana Golberstein, who is a chemist and licenced pharmacist here in New Zealand, reviewed the CAPHRA submission for the veracity of the chemistry and science references. I, in turned reviewed submission for clarity in English (as it is not her native language) prior to making our submissions.

QoN 05

Did you make inquiries as to whether the persons/organisations you consulted or liaised with receive any support, whether financial or non-financial, direct or indirect, from parties involved in the production, distribution or sale of tobacco, nicotine or vaping products?

If yes, please provide the details of those inquiries, including:

- a. what assurances were sought;
- b. dates of those inquiries; and
- c. whether they were made in written form or orally.

We are aware that Eliana and her company Myriad Pharmaceuticals are involved in the production of nicotine and nicotine salts that are used for electronic cigarettes for scientific research. Eliana is a scientific advisor to CAPHRA and its member organisations on all matters of chemistry and pharmaceuticals.



QoN 06

Have you, or any organisation with which you are associated, received any support, whether financial or non-financial, direct or indirect, from the following organisations, or persons associated with, the following organisations:

- a. The Institute for Public Affairs;
- b. Centre for Independent Studies;
- c. The Sydney Institute;
- d. Australian Taxpayers Alliance;
- e. Australian Institute For Progress;
- f. Mannkal Economic Education Foundation;
- g. Legalise Vaping Australia; and
- h. any ATLAS network member organisation.

Neither CAPHRA nor myself personally have received any support, whether financial or non financial, direct or indirect from the organisations listed in this question.



QoN 07

Please provide the details of supporting given by the organisations listed in question 4, including:

- a. name of the organisation;
- b. nature of the support;
- c. amount or value provided; and
- d. any other related information.

Eliana Golberstein of Myriad Pharmaceuticals in Auckland NZ provided editorial review of the CAPHRA submission to clarify that any scientific information included was correct. I, in turn, provided editorial review of her submission to check for the consistency of the English used therein as it is not her native language.

There is no amount or value provided for this service to or from either party.

QoN 08

Have you consulted, or had any contact with the groups or persons associated with groups listed in question 4, regarding your submission to this inquiry, or regarding your policy on vaping, tobacco, nicotine or any related products?

If yes, please provide the details of the organisations listed in question 4 with which you had contact, including:

- a. name of the organisation; and
- b. what the nature of the contact was.

Aside from what has already been disclosed, (editorial review of CAPHRA submission to scientific clarity by Eliana Golberstein of Myriad Pharmaceuticals, there were no other consultations. I did not discuss with Eliana anything beyond the scientific merit of what was included in the CAPHRA submission.